Inicio > BIGG > Resultado de la búsqueda

    Resultados: 5

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged 2 through 18 years with underlying medical conditions

    MMWR recomm. rep; 72 (39), 2023
    On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
    Vacuna Neumocócica Conjugada Heptavalente/uso terapéutico, Infecciones Neumocócicas/prevención & control, Inmunogenicidad Vacunal, Comorbilidad
    Texto completo

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years

    MMWR recomm. rep; 72 (39), 2023
    On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
    Vacuna Neumocócica Conjugada Heptavalente/uso terapéutico, Infecciones Neumocócicas/prevención & control, Inmunogenicidad Vacunal
    Texto completo

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged 19–64 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)

    MMWR recomm. rep; 72 (3), 2023
    On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
    Vacuna Neumocócica Conjugada Heptavalente/inmunología, Huésped Inmunocomprometido, Implantación Coclear, Pérdida de Líquido Cefalorraquídeo
    Texto completo

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged ≥65 years who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)

    MMWR recomm. rep; 72 (3), 2023
    On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
    Vacuna Neumocócica Conjugada Heptavalente, Programas de Inmunización, Neumonía Neumocócica/inmunología
    Texto completo

    GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged <2 years

    MMWR recomm. rep; 71 (37), 2022
    On June 22, 2022, ACIP recommended use of 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) as an option for pneumococcal conjugate vaccination for persons aged <19 years according to currently recommended PCV13 dosing and schedules. A systematic review and Grading o...
    Infecciones Neumocócicas/inmunología, Vacuna Neumocócica Conjugada Heptavalente/uso terapéutico, Inmunogenicidad Vacunal
    Texto completo